Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma - Wikidata - awgldk - TriplyDB

Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma

Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma

http://www.wikidata.org/entity/Q27000310

about

Targeted Radionuclide Therapy of Human Tumors Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma

P2860

Q26771267-5DD4CDA0-CB46-4497-9A67-EDFF46EEA65B Q35786490-A8859CBD-0991-4644-A69F-69F4873F91FA

P2860

Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma

http://www.wikidata.org/entity/Q27000310

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@ast

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@en

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@nl

type

label

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@ast

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@en

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@nl

prefLabel

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@ast

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@en

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@nl

P1433

Q27000310-85808F3C-58EB-487C-B13E-C1DCC7F4123F

P1476

Q27000310-EB4B6428-6214-46C3-8005-11812CBD75A4

P2093

Q27000310-A785F8CC-B18D-4AED-9064-5E371B1253A8

Q27000310-A824D8A1-3C64-4229-8FEA-FAABD0F0DE53

P2860

Q27000310-0B24AB55-946F-4BC9-B7A5-1A306C3740D5

Q27000310-0F373E8B-3DFF-4EEB-97CE-37509EB76F28

Q27000310-107D88BC-BACB-4FBE-949A-EB40429A6323

Q27000310-12CB5DE1-435E-4485-BF49-049C8648ADF7

Q27000310-148B4F4B-2D65-44B3-AA31-4588358060C3

Q27000310-18DA3D35-F33B-4090-8F3F-2A1C3B594313

Q27000310-1BF6A4A2-C048-4001-9E82-E9B1F6AEC55B

Q27000310-1C570558-884C-4912-B111-52915BDDAB38

Q27000310-2217FE5F-11CC-43C0-806E-AF12E02BE5B8

Q27000310-22CA87C3-DD54-4F67-9FAC-B515D588C0A7

P304

Q27000310-11990F72-58B4-467F-9B13-9915B2044286

P31

Q27000310-B0175DBB-5FBC-429E-AABE-13B0099AFADA

P356

Q27000310-21FBAF7F-5A6D-4F72-911B-CA081855D9E5

P407

Q27000310-03737B1F-2947-46D7-8BEA-A978E073044C

P433

Q27000310-3CA09ECD-2D2E-4999-87B0-3C0CDA16C693

P478

Q27000310-CA767479-9C0A-4B44-869C-B42316AD822B

P50

Q27000310-DF0A0889-143F-4311-A274-076E6B84507F

P577

Q27000310-7966786C-52BD-4768-B83E-F3918EF51089

P5875

Q27000310-9B71E770-F8D8-4399-9B70-7788422AEB16

P698

Q27000310-F55785F6-333F-466A-9990-5194F59BAC75

P932

Q27000310-07822146-6D1F-4496-A72E-0E787FCCFC8B

P356

2040620714532282

P1433

Therapeutic advances in hematology

P1476

Role of consolidation with ytt ...... nced-stage follicular lymphoma

@en

P2093

Antonio C Sánchez Ruiz

http://www.w3.org/2001/XMLSchema#string

Luis de la Cruz-Merino

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2014

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma.

P304

78-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040620714532282

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Mariano Provencio

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262781840

http://www.w3.org/2001/XMLSchema#string

P698

24883180

http://www.w3.org/2001/XMLSchema#string

P932

4031906

http://www.w3.org/2001/XMLSchema#string